Three next-generation drugs lead the pipeline. Retatrutide is an investigational "triple agonist" (GLP-1 + GIP + glucagon) from Eli Lilly that produced large weight loss in trials but was not approved as of 2026. Orforglipron is Lilly's oral, non-peptide GLP-1 pill with no strict food-and-water timing — it reached the U.S. market in 2026 as Foundayo for weight management. CagriSema is Novo Nordisk's once-weekly combination of cagrilintide plus semaglutide, which the company submitted to the FDA in late 2025 and was under review in 2026. Approval status and availability change fast — always confirm the current label with the FDA or manufacturer.
Key takeaways
- The field is moving toward multi-receptor drugs and oral options, not just weekly injections.
- Retatrutide hits three receptors and posted big trial numbers, but remained investigational in 2026.
- Orforglipron (Foundayo) is a daily pill that reached the market in 2026 — no water-and-fasting ritual required.
- CagriSema pairs an amylin analogue with semaglutide and was under FDA review in 2026.
Why so many new GLP-1 drugs at once?
The first generation of GLP-1 medications — semaglutide and tirzepatide — proved two things at once: that these drugs can drive weight loss no earlier pill ever matched, and that demand is enormous. That combination pulled a huge amount of research money into the space, and the result is a pipeline aimed at three goals: bigger effect (by hitting more than one hormone receptor), easier delivery (pills instead of injections), and broader use (diabetes, obesity, and related conditions). The three drugs below are the clearest examples of each direction. For the fundamentals of how this drug class works, see our what is GLP-1 explainer.
What is retatrutide?
Retatrutide is Eli Lilly's investigational triple agonist: a single injectable that activates three receptors — GLP-1, GIP and glucagon — rather than one or two. The thinking is that engaging glucagon in addition to the two incretin pathways may push weight loss and metabolic improvement further. In clinical trials it produced notably large weight reductions, which is why it generates so much excitement, and it also posted positive late-stage results in type 2 diabetes.
The important caveat: retatrutide was not FDA-approved as of 2026. It remained in late-stage development, and industry watchers generally expect a potential launch later in the decade rather than immediately. Trial numbers are promising, but they aren't the same as a finished, approved product with a full safety label — so treat any "retatrutide is the strongest GLP-1" claims as being about research, not a prescription you can fill today.
What is orforglipron?
Orforglipron is Eli Lilly's oral, non-peptide GLP-1 receptor agonist. That "non-peptide" detail matters: the existing oral semaglutide (Rybelsus) is a peptide and has to be taken on an empty stomach with a specific small sip of water and a waiting period before eating. Because orforglipron is built as a small molecule instead, it's designed to be taken as a daily pill without those strict food-and-water rules — a genuinely different convenience story, and a big deal for people who dislike injections.
Unlike retatrutide, orforglipron crossed the finish line: it reached the U.S. market in 2026 under the brand name Foundayo for chronic weight management. If you're weighing a pill against a weekly shot, our pill vs. injection guide walks through the trade-offs. As always, whether any specific product is right for you — and whether it's covered — is a conversation for a clinician, and the exact approved uses and dosing live in the current FDA label.
What is CagriSema?
CagriSema is Novo Nordisk's answer to the multi-hormone trend, but it takes a different route than a triple agonist. It's a once-weekly injectable combination of two ingredients: cagrilintide, a long-acting amylin analogue, and semaglutide, the GLP-1 agonist already familiar from Ozempic and Wegovy. Amylin is a separate satiety hormone, so the idea is that pairing it with a GLP-1 hits appetite regulation through two complementary pathways.
In late-stage trials, CagriSema produced substantial weight loss. Novo Nordisk submitted its application to the FDA in late 2025, and the drug was under review in 2026 — meaning it was not yet approved as this was written. Whether and when it becomes available, and for which uses, depends on that review, so this is one to confirm against official sources rather than assume.
| Drug | Maker | Type | Delivery | Status as of 2026 |
|---|---|---|---|---|
| Retatrutide | Eli Lilly | Triple agonist (GLP-1 + GIP + glucagon) | Injection | Investigational — not approved |
| Orforglipron (Foundayo) | Eli Lilly | Oral non-peptide GLP-1 agonist | Daily pill, no food/water timing | Reached U.S. market in 2026 for weight management |
| CagriSema | Novo Nordisk | Cagrilintide (amylin) + semaglutide (GLP-1) | Once-weekly injection | Submitted to FDA late 2025; under review |
What this pipeline means for you
The headline is choice. Within a couple of years the menu has widened from "which weekly injection" to include an oral option that skips the fasting ritual, a combination shot working on two hormones, and a triple agonist waiting in the wings. That's good news for people who've struggled with injections, tolerability or plateaus. But three cautions are worth keeping front of mind. First, trial results aren't the same as your results — averages hide a wide range, and side-effect profiles matter as much as peak numbers. Second, approval status and availability move quickly; a drug that's "under review" today may be approved (or delayed) by the time you read this. Third, newer and stronger isn't automatically better for you — coverage, cost, tolerability and your own health picture all factor in. See our full medications guide for how the approved options compare, and make the final call with a clinician.
Frequently asked questions
What new GLP-1 drugs are coming?
The most talked-about are retatrutide (investigational triple agonist, Eli Lilly), orforglipron (oral non-peptide GLP-1 agonist, Eli Lilly, which reached the U.S. market in 2026 as Foundayo), and CagriSema (cagrilintide + semaglutide, Novo Nordisk, under FDA review in 2026). Others are in earlier development.
What is retatrutide?
An investigational injectable from Eli Lilly that activates three receptors — GLP-1, GIP and glucagon — hence "triple agonist." It produced large weight loss in trials but was not FDA-approved as of 2026 and remains in late-stage development.
What is orforglipron?
An oral, non-peptide GLP-1 receptor agonist from Eli Lilly. Because it isn't a peptide, it can be taken as a daily pill without the strict food-and-water timing Rybelsus requires. It reached the U.S. market in 2026 under the brand name Foundayo for chronic weight management.
What is CagriSema?
A once-weekly injectable combination from Novo Nordisk pairing cagrilintide (an amylin analogue) with semaglutide (a GLP-1 agonist). It showed substantial weight loss in late-stage trials; Novo Nordisk submitted it to the FDA in late 2025 and it was under review in 2026, not yet approved.
Sources & further reading
- U.S. Food & Drug Administration — approvals, drug database and prescribing information for GLP-1 and related products.
- Eli Lilly and Company — press releases and pipeline updates for retatrutide and orforglipron (Foundayo).
- Novo Nordisk — press releases on the CagriSema regulatory submission and late-stage trial results.